Search review questions

Interferon beta or glatiramer acetate · relapsing multiple sclerosis

Ocrelizumab · relapsing multiple sclerosis

Interferon beta or glatiramer acetate · relapsing multiple sclerosis

Dimethyl fumarate · relapsing multiple sclerosis

Natalizumab · relapsing multiple sclerosis

Fingolimod · relapsing multiple sclerosis

Disability worsening measured by EDSS over 24 months · primary progressive multiple sclerosis

Relapse measured by clinical assessment over 24 months · primary progressive multiple sclerosis

Serious adverse events measured by clinical assessment over 28 months · primary progressive multiple sclerosis

Relapse(assessed as number of participants experiencing relapse) · adults with multiple sclerosis, defined by established criteria

SAEs (assessed as number of participants experiencing a SAE) · adults with multiple sclerosis, defined by established criteria

Relapse(assessed as number of participants experiencing relapse) · adults with multiple sclerosis, defined by established criteria

Change in validated disability scale ( · adults with multiple sclerosis, defined by established criteria

Global impression of deterioration (investigator defined global impression of deterioration) · adults with multiple sclerosis, defined by established criteria

MRI activity(assessed as number of participants with gadolinium‐enhancing lesions) · adults with multiple sclerosis, defined by established criteria

SAEs (assessed as number of participants experiencing a SAE) · adults with multiple sclerosis, defined by established criteria

Change in validated disability scale ( · adults with multiple sclerosis, defined by established criteria

Global impression of deterioration (investigator defined global impression of deterioration) · adults with multiple sclerosis, defined by established criteria

MRI activity ‐ not measured · adults with multiple sclerosis, defined by established criteria

SAEs (assessed as number of participants experiencing a SAE) · adults with multiple sclerosis, defined by established criteria

Relapse(assessed as number of participants experiencing relapse) · adults with multiple sclerosis, defined by established criteria

Change in validated disability scale ( · adults with multiple sclerosis, defined by established criteria

Global impression of deterioration (investigator defined global impression of deterioration) · adults with multiple sclerosis, defined by established criteria

MRI activity(assessed by new gadolinium‐enhancing lesions) · adults with multiple sclerosis, defined by established criteria

Treatment failure: morbidity associated with shunt placement that led to shunt revision · participants with hydrocephalus

Quality of life · participants with hydrocephalus

Treatment failure: morbidity associated with shunt placement that led to shunt revision · participants with hydrocephalus

Adverse events: morbidity related to the shunt placement that has not led to shunt revision · participants with hydrocephalus

Mortality In the early postoperative period (≤ 30 days) · participants with hydrocephalus

Mortality Beyond the early postoperative period (> 30 days) · participants with hydrocephalus

Quality of life · participants with hydrocephalus

Treatment failure: morbidity associated with shunt placement that led to shunt revision · participants with hydrocephalus

Adverse events: morbidity related to the shunt placement that has not led to shunt revision · participants with hydrocephalus

Mortality In the early postoperative period (≤30 days) · participants with hydrocephalus

Mortality Beyond the early postoperative period (>30 days) · participants with hydrocephalus

Adverse events: morbidity related to the shunt placement that has not led to shunt revision · participants with hydrocephalus

Quality of life · participants with hydrocephalus

Mortality In the early postoperative period (≤ 30 days) · participants with hydrocephalus

Mortality Beyond the early postoperative period (> 30 days) · participants with hydrocephalus

Quality of life · participants with hydrocephalus

Treatment failure: morbidity associated with shunt placement that led to shunt revision · participants with hydrocephalus

Adverse events: morbidity related to the shunt placement that has not led to shunt revision · participants with hydrocephalus

Mortality In the early postoperative period (≤ 30 days) · participants with hydrocephalus

Mortality Beyond the early postoperative period (> 30 days) · participants with hydrocephalus

Proportion of participants who experienced operative or postoperative serious adverse events · patients with multiple sclerosis and chronic cerebrospinal venous insufficiency (CCSVI)

Proportion of participants who experienced improvement of composite functional endpoint over 12 months · patients with multiple sclerosis and chronic cerebrospinal venous insufficiency (CCSVI)

Proportion of participants who experienced new relapses over 12 months · patients with multiple sclerosis and chronic cerebrospinal venous insufficiency (CCSVI)

Falls rate Falls were measured using prospective daily diaries, prospective monthly calendars or retrospectively. Falls rate calculation= number of falls/number in group * (number of days/365) The timing of measurement was post‐intervention for al... · people with multiple sclerosis (including people with relapsing‐remitting, secondary progressive or primary…

Number of fallers Falls were measured using prospective daily diaries, prospective monthly calendars or retrospectively The timing of measurement was post‐intervention for all studies · people with multiple sclerosis (including people with relapsing‐remitting, secondary progressive or primary…

Adverse events The timing of measurement was post‐intervention for all studies · people with multiple sclerosis (including people with relapsing‐remitting, secondary progressive or primary…